"Médicaments Prix Aspect moral." . . "Fibrinolytica." . . "Clinical Trials as Topic economics United States." . . "Fibrinolytiques." . . . . "Drug Approval economics United States." . . "Farmaci Costi Apetti etico-morali." . . "Autorisation de mise sur le marché d'un médicament Économie États Unis d'Amérique." . . "Clinical trials." . . "clinical trials" . "Ethische aspecten." . . "Farmaci fibrinolitici Consumo Stati Uniti." . . "expérimentation sur les êtres humains médicament morale médicale prix." . . "Sang Coagulation Effets des médicaments." . . "Médicaments Essais cliniques Aspect moral." . . "Farmaci Sperimentazione clinica Aspetti etico-morali." . . "Approvazione di farmaci Stati Uniti." . . "Geneesmiddelen." . . "Farmaci Marketing Stati Uniti." . . . . . . . . . . . . . . "Ethical issues in drug testing, approval, and pricing the clot-dissolving drugs"@en . . . . . . "Although most developed countries have extensive regulations governing the testing, approval and marketing of new drugs, there are major gaps in these regulations. In this compelling new volume, Dr. Brody uses the example of the development of thrombolytic drugs to identify several such gaps. Issues addressed include the use of placebo control groups in clinical trials, the importance of determining the type of consent that should be obtained for emergency research, and ways to avoid conflicts of interest in clinical trials. He also discusses topics such as deciding to continue clinical trials or to approve a drug quickly, maintaining a proper balance between efficacy and safety in drug approval, the pricing of new drugs and considering prices when ordering drugs. This work offers the first comprehensive analysis from an ethical perspective of the entire drug development process, and it does so while comparing American and European approaches to the process." . "Although most developed countries have extensive regulations governing the testing, approval and marketing of new drugs, there are major gaps in these regulations. In this compelling new volume, Dr. Brody uses the example of the development of thrombolytic drugs to identify several such gaps. Issues addressed include the use of placebo control groups in clinical trials, the importance of determining the type of consent that should be obtained for emergency research, and ways to avoid conflicts of interest in clinical trials. He also discusses topics such as deciding to continue clinical trials or to approve a drug quickly, maintaining a proper balance between efficacy and safety in drug approval, the pricing of new drugs and considering prices when ordering drugs. This work offers the first comprehensive analysis from an ethical perspective of the entire drug development process, and it does so while comparing American and European approaches to the process."@en . "Ethical issues in drug testing, approval, and pricing : the clot-dissolving drugs" . . . . . . . . . . . . . "Ethical issues in drug testing, approval, and pricing : The clot-dissolving drugs" . . . . . . . . "Fibrinolytic Agents United States." . . "drug approval" . . "Essais cliniques comme sujet Économie États Unis d'Amérique." . . "ethics" . .